Full Press Release Details
Frost and Sullivan Honors Oramed
with the 2009 European Oral Drug Delivery Technology
JERUSALEM, Israel, August 25
/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc.
(OTCBB: ORMP.OB) ( http://www.oramed.com), a developer of oral delivery systems,
today announced that it is the
recipient of the 2009 Frost & Sullivan European Oral Drug Delivery
Technology Innovation Award.
Oramed Pharmaceuticals is
developing a platform technology to create oral delivery systems for drugs and
vaccines delivered via injection. Oramed focuses on the treatment of
diabetes through its proprietary flagship product, an Oral Insulin capsule that
is currently in Phase 2b clinical trials. Oramed's research pipeline also
includes other product candidates, such as an Oral GLP-1 Analog
"We are honored to receive
the 2009 European Oral Drug Delivery Technology Innovation Award," said Nadav
Kidron, Esq., Oramed's CEO. "Being recognized for our leadership position in the oral
drug delivery field by Frost & Sullivan is an encouraging validation of our
& Sullivan's Technology Innovation Awards recognize companies in a variety
of regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service and strategic product development. Industry analysts compare
market participants and measure performance through in-depth interviews,
analysis and extensive secondary research in order to identify best practices in
& Sullivan, the Growth Partnership Company, partners with clients to
accelerate their growth. The company's TEAM Research, Growth Consulting and
Growth Team Membership(TM) empower clients to create a growth-focused culture
that generates, evaluates and implements effective growth strategies. Frost
& Sullivan employs over 45 years of experience in partnering with Global
1000 companies, emerging businesses and the investment community from more than
30 offices on six continents. For more information about Frost & Sullivan's
Growth Partnerships, visit http://www.frost.com.
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
For more information, please visit
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
and Investor Relations Contact:
Int'l:+972-54-334-4318